MannKind Corp (MNKD) Stock AnalysisMNKDMannKind Corp

MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

MannKind Corp is not a strong buy at the moment due to its current price of $3.04, which is significantly below analyst targets. The stock has a low RSI of 30.74, indicating oversold conditions, but it also has a high forward P/E of 25.71, suggesting potential overvaluation. The recent FDA approval for Furoscix and a revenue increase of 43% year-over-year are positive signs, but the company reported a net loss of $19 million in Q2 2026, which raises concerns about profitability. The main risk is the 337.78% increase in hedge fund selling, indicating a lack of confidence among institutional investors.

2 analysts cover MNKD: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.25.